Troy A. Ignelzi - 19 Apr 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 19 Apr 2022
Net transactions value: -$517,941
Form type: 4
Filing time: 21 Apr 2022, 19:04:30 UTC
Previous filing: 17 Feb 2022
Next filing: 11 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$32,200	+3,500	+14%	$9.20^*	28,470	19 Apr 2022	Direct
transaction	KRTX	Common Stock	Sale	$457,835	-3,500	-12%	$130.81	24,970	19 Apr 2022	Direct	F1, F2
transaction	KRTX	Common Stock	Options Exercise	$6,477	+704	+2.8%	$9.20^*	25,674	20 Apr 2022	Direct
transaction	KRTX	Common Stock	Sale	$93,773	-704	-2.7%	$133.20	24,970	20 Apr 2022	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$368	+40	+0.16%	$9.20^*	25,010	21 Apr 2022	Direct
transaction	KRTX	Common Stock	Sale	$5,378	-40	-0.16%	$134.46	24,970	21 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-3,500	-2.2%	$0.000000	155,356	19 Apr 2022	Common Stock	3,500	$9.20	Direct	F3
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-704	-0.45%	$0.000000	154,652	20 Apr 2022	Common Stock	704	$9.20	Direct	F3
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-40	-0.03%	$0.000000	154,612	21 Apr 2022	Common Stock	40	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $130.78 to $130.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.